Albion Financial Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Albion Financial Group’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$109	–	662
2025 Q2	$109	Hold	200	–	–	﹤0.01%	571
2025 Q1	$132	Hold	200	–	–	﹤0.01%	588
2024 Q4	$204	Hold	200	–	–	﹤0.01%	661
2024 Q3	$174	Hold	200	–	–	﹤0.01%	493
2024 Q2	$72	Hold	200	–	–	﹤0.01%	503
2024 Q1	$135	Hold	200	–	–	﹤0.01%	487
2023 Q4	$109	Hold	200	–	–	﹤0.01%	467
2023 Q3	$120	Hold	200	–	–	﹤0.01%	465
2023 Q2	$260	Hold	200	–	–	﹤0.01%	452
2023 Q1	$352	Hold	200	–	–	﹤0.01%	424
2022 Q4	$628	Hold	200	–	–	﹤0.01%	449
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	428
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	508
2022 Q1	$1K	Hold	200	–	–	﹤0.01%	573
2021 Q4	$2K	Hold	200	–	–	﹤0.01%	544
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	467
2021 Q2	$2K	Buy	+200	New	+$2.26K	﹤0.01%	463
2020 Q4	$3K	Buy	+200	New	+$2.34K	﹤0.01%	411

Other funds holding SGMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Albion Financial Group's SGMO Position: Q3 2025 in Review

Albion Financial Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025, closing a stake of 200 shares — an estimated $109 sold.

Albion Financial Group first reported a position in SGMO in Q4 2020 and held it in 18 quarters. The position peaked at $3K in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

Albion Financial Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
Albion Financial Group sold 200 SANGAMO THERAPEUTICS INC shares in Q3 2025, an estimated $109.
Albion Financial Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2020 and held it in 18 quarters.
Albion Financial Group's SANGAMO THERAPEUTICS INC position peaked at $3K in Q4 2020.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Albion Financial Group's 13F filing for Q3 2025, filed 20 Oct 2025.